Preservation of Immune Effector Cell Function Following Administration of a Dose-intense 5-fluorouracil-chemotherapy Regimen

Overview

Journal Cancer Immunol Immunother

Specialties Allergy & Immunology
Oncology
Pharmacology

Date 1993 Jan 1

PMID 8439979

Authors

L M Weiner

G R Hudes

J Kitson

J Walczak

P Watts

S Litwin

P J ODwyer

Affiliations

Soon will be listed here.

Abstract

In a phase II clinical trial of 5-fluorouracil (5FU) plus N-(phosphonacetyl)-L-aspartate (PALA) therapy administration, a number of slowly developing clinical responses were observed. Because of this, a variety of immune parameters were sequentially studied in 21 patients on this trial. Of the 21 patients studied, 20 provided sufficient samples to compare baseline with subsequent values, 10 of the 20 patients responded to treatment. Responders and non-responders did not differ in any studied parameter at baseline. After 2 months of therapy, non-specific monocyte cytotoxicity (NSMC), antibody-dependent monocyte cytotoxicity (ADMC) and natural killer (NK) activity were higher in the entire study population, but these increases were not statistically significant. When responders and non-responders were evaluated separately, it was apparent that the trend was due solely to the changes observed in the responding patient population. When mean lysis values for each patient group were determined for each studied time point, it was possible to generate a mean area under the cytotoxicity/time curve (AUC) for each studied parameter. NSMC and ADMC did not differ in responders and non-responders. However, NK activity was significantly greater by mean AUC analysis (P = 0.006) in the responding group; NK activity was maintained in the responders, but decreased in non-responders. When lymphocyte and monocyte expression of the surface markers beta 2-microglobulin, HLA-DR, CD56, HNK-1, CD16 and interleukin-2 receptor were evaluated, there were no differences among responders and non-responders at baseline by mean AUC analysis or when comparing baseline with non-baseline values. It is concluded that although baseline immunological characteristics do not identify patients who are likely to respond to weekly 5FU and PALA, treatment is not associated with deleterious effects on the immune effector function parameters evaluated in this study, there being no effects on expression of a variety of associated cell-surface molecules.

References

Shih W, Baumhefner R, Tourtellotte W, Haskell C, Korn E, Fahey J . Difference in effect of single immunosuppressive agents (cyclophosphamide, CCNU, 5-FU) on peripheral blood immune cell parameters and central nervous system immunoglobulin synthesis rate in patients with multiple sclerosis. Clin Exp Immunol. 1983; 53(1):122-32. PMC: 1535539. View

ODwyer P, Paul A, Walczak J, Weiner L, Litwin S, Comis R . Phase II study of biochemical modulation of fluorouracil by low-dose PALA in patients with colorectal cancer. J Clin Oncol. 1990; 8(9):1497-503. DOI: 10.1200/JCO.1990.8.9.1497. View

Wadler S, Schwartz E, Goldman M, Lyver A, Rader M, Zimmerman M . Fluorouracil and recombinant alfa-2a-interferon: an active regimen against advanced colorectal carcinoma. J Clin Oncol. 1989; 7(12):1769-75. DOI: 10.1200/JCO.1989.7.12.1769. View

Mitchell M, DeConti R . Immunosuppression by 5-fluorouracil. Cancer. 1970; 26(4):884-9. DOI: 10.1002/1097-0142(197010)26:4<884::aid-cncr2820260422>3.0.co;2-s. View

Grem J, Allegra C . Toxicity of levamisole and 5-fluorouracil in human colon carcinoma cells. J Natl Cancer Inst. 1989; 81(18):1413-7. DOI: 10.1093/jnci/81.18.1413. View

Ben-Efraim S, Shoval S, Ophir R . The difference between 5-fluorouracil and melphalan in their ability to promote antitumor immune response against MOPC-315 plasmacytoma. Cancer Immunol Immunother. 1986; 22(1):43-8. PMC: 11038600. DOI: 10.1007/BF00205715. View

MOERTEL C, Fleming T, Macdonald J, Haller D, Laurie J, Goodman P . Levamisole and fluorouracil for adjuvant therapy of resected colon carcinoma. N Engl J Med. 1990; 322(6):352-8. DOI: 10.1056/NEJM199002083220602. View

Weiner L, Kitson J, Watts P, Krigel R, Litwin S . Phase I evaluation of combination therapy with interleukin 2 and gamma-interferon. Cancer Res. 1991; 51(15):3910-8. View

Ardalan B, Singh G, SILBERMAN H . A randomized phase I and II study of short-term infusion of high-dose fluorouracil with or without N-(phosphonacetyl)-L-aspartic acid in patients with advanced pancreatic and colorectal cancers. J Clin Oncol. 1988; 6(6):1053-8. DOI: 10.1200/JCO.1988.6.6.1053. View

10.

Harris J, Sengar D, Stewart T, Hyslop D . The effect of immunosuppressive chemotherapy on immune function in patients with malignant disease. Cancer. 1976; 37(2 Suppl):1058-69. DOI: 10.1002/1097-0142(197602)37:2+<1058::aid-cncr2820370813>3.0.co;2-o. View

11.

Sindelar W, Maher M, Herlyn D, Sears H, Steplewski Z, KOPROWSKI H . Trial of therapy with monoclonal antibody 17-1A in pancreatic carcinoma: preliminary results. Hybridoma. 1986; 5 Suppl 1:S125-32. View

12.

BLOMGREN S, WOLBERG W, KISKEN W . Effect of fluoropyrimidines on delayed cutaneous hypersensitivity. Cancer Res. 1965; 25(7):977-9. View

13.

Pross H, Baines M, Rubin P, Shragge P, Patterson M . Spontaneous human lymphocyte-mediated cytotoxicity against tumor target cells. IX. The quantitation of natural killer cell activity. J Clin Immunol. 1981; 1(1):51-63. DOI: 10.1007/BF00915477. View

14.

Sears H, Herlyn D, Steplewski Z, KOPROWSKI H . Phase II clinical trial of a murine monoclonal antibody cytotoxic for gastrointestinal adenocarcinoma. Cancer Res. 1985; 45(11 Pt 2):5910-3. View

15.

Boyum A . Separation of leukocytes from blood and bone marrow. Introduction. Scand J Clin Lab Invest Suppl. 1968; 97:7. View

16.

Tokuda N, Gondo H, Mayumi H, Taniguchi K, Himeno K, Nomoto K . Drug-induced in vitro tolerance to allogeneic antigens. I. Establishment of a tolerance induction system in a fully allogeneic murine combination. Transplantation. 1986; 42(3):281-7. DOI: 10.1097/00007890-198609000-00011. View

17.

Rosenberg S, Lotze M, Muul L, Chang A, Avis F, Leitman S . A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone. N Engl J Med. 1987; 316(15):889-97. DOI: 10.1056/NEJM198704093161501. View

18.

Goto M, Mitsuoka A, Sugiyama M, Kitano M . Enhancement of delayed hypersensitivity reaction with varieties of anti-cancer drugs. A common biological phenomenon. J Exp Med. 1981; 154(1):204-9. PMC: 2186397. DOI: 10.1084/jem.154.1.204. View

19.

Sears H, Atkinson B, Mattis J, Ernst C, Herlyn D, Steplewski Z . Phase-I clinical trial of monoclonal antibody in treatment of gastrointestinal tumours. Lancet. 1982; 1(8275):762-5. DOI: 10.1016/s0140-6736(82)91811-6. View

20.

Freundlich B, Avdalovic N . Use of gelatin/plasma coated flasks for isolating human peripheral blood monocytes. J Immunol Methods. 1983; 62(1):31-7. DOI: 10.1016/0022-1759(83)90107-2. View